Alnylam's Givosiran Looks Positive Overall in Phase III Trial for Rare Disease

Despite releasing positive data on its Phase III ENVISION trial, Alnylam Pharmaceuticals stock dropped 7.5 percent. Although not completely clear why, the drop may be related to a high percentage of serious adverse events observed in the trial. The ENVISION Phase III trial evaluated givosiran, an investigational RNAi therapeutic that targets aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP).
Read more...

;